全文获取类型
收费全文 | 232260篇 |
免费 | 16637篇 |
国内免费 | 876篇 |
专业分类
耳鼻咽喉 | 2572篇 |
儿科学 | 5921篇 |
妇产科学 | 4734篇 |
基础医学 | 30180篇 |
口腔科学 | 4996篇 |
临床医学 | 21995篇 |
内科学 | 49871篇 |
皮肤病学 | 3047篇 |
神经病学 | 22490篇 |
特种医学 | 7804篇 |
外国民族医学 | 13篇 |
外科学 | 35864篇 |
综合类 | 3651篇 |
现状与发展 | 2篇 |
一般理论 | 337篇 |
预防医学 | 20884篇 |
眼科学 | 5234篇 |
药学 | 15629篇 |
1篇 | |
中国医学 | 407篇 |
肿瘤学 | 14141篇 |
出版年
2023年 | 929篇 |
2022年 | 1583篇 |
2021年 | 3845篇 |
2020年 | 2341篇 |
2019年 | 3745篇 |
2018年 | 4402篇 |
2017年 | 3553篇 |
2016年 | 3787篇 |
2015年 | 4491篇 |
2014年 | 6722篇 |
2013年 | 9692篇 |
2012年 | 14452篇 |
2011年 | 15773篇 |
2010年 | 8894篇 |
2009年 | 8067篇 |
2008年 | 14886篇 |
2007年 | 15777篇 |
2006年 | 15126篇 |
2005年 | 15686篇 |
2004年 | 14954篇 |
2003年 | 14003篇 |
2002年 | 13516篇 |
2001年 | 2174篇 |
2000年 | 1742篇 |
1999年 | 2365篇 |
1998年 | 3055篇 |
1997年 | 2691篇 |
1996年 | 2409篇 |
1995年 | 2126篇 |
1994年 | 1881篇 |
1993年 | 1778篇 |
1992年 | 1408篇 |
1991年 | 1332篇 |
1990年 | 1236篇 |
1989年 | 1096篇 |
1988年 | 1161篇 |
1987年 | 1159篇 |
1986年 | 1147篇 |
1985年 | 1233篇 |
1984年 | 1635篇 |
1983年 | 1602篇 |
1982年 | 1952篇 |
1981年 | 1805篇 |
1980年 | 1683篇 |
1979年 | 938篇 |
1978年 | 1065篇 |
1977年 | 1040篇 |
1976年 | 908篇 |
1975年 | 795篇 |
1974年 | 765篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
61.
John Hawk 《Photodermatology, photoimmunology & photomedicine》2002,18(3):146-146
62.
Infantile Digital Fibroma Treated With Mohs Micrographic Surgery 总被引:2,自引:0,他引:2
John G. Albertini MD Maj USAF MC Michael Jude Welsch MD CPT USA MC Leo A. Conger MD LTC USA MC Lester F. Libow MD COL USA MC Dirk M. Elston MD COL USA MC 《Dermatologic surgery》2002,28(10):959-961
BACKGROUND: Infantile digital fibroma (IDF) is a rare benign fibrous tumor of childhood that frequently recurs despite local excision. Conservative, nonsurgical management may result in regression and/or joint deformity. OBJECTIVE: To describe the histologic features of IDF and discuss a case excised using Mohs micrographic surgery (MMS). METHODS: Case report and review of the clinical, histologic, and ultrastructural features. RESULTS: Characteristic inclusion bodies of actin were identified with hematoxylin and eosin, Masson's trichrome, and rapid actin immunostain. The tumor was debulked and the majority was removed after one stage of MMS, except where the deep margin approached the joint space. The defect healed by secondary intention. At 2 years the patient had no recurrence or functional joint deformity. CONCLUSION: MMS is a surgical treatment option for IDF. 相似文献
63.
Dipankar Nandi Helen Smith Sarah Owen Carole Joint John Stein Tipu Aziz 《Journal of clinical neuroscience》2002,9(5):557-561
Central post stroke pain is often difficult to manage satisfactorily with conventional treatment modalities for pain. In the last decade functional neurosurgery has offered hope with motor cortex stimulation achieving significant alleviation of pain in some patients. Unfortunately this has led to the neglect of chronic stimulation of deep grey matter as another modality of treating this condition. In this article we present our experience with motor cortex stimulation and that with deep grey matter stimulation in patients with post stroke pain. We argue that both modalities have a significant role and that what is required are better methods of identifying particular patients who are more likely to respond to one or the other. 相似文献
64.
Guerard W. Byrne Johannes M. Schirmer David N. Fass Sumeet S. Teotia Walter K. Kremers Hui Xu Bashoo Naziruddin Henry D. Tazelaar John S. Logan Christopher G. A. McGregor 《American journal of transplantation》2005,5(5):1011-1020
Microvascular thrombosis is a prominent feature in cardiac delayed xenograft rejection (DXR). We investigated the impact of warfarin or low-molecular-weight heparin (LMWH) anti-coagulation on xenograft function using a heterotopic pig-to-primate model. Donor hearts were from CD46 transgenic pigs and baboon immunosuppression included tacrolimus, sirolimus, anti-CD20 and TPC, an alpha-galactosyl-polyethylene glycol conjugate. Three groups of animals were studied. Group 1 (n = 9) was treated with warfarin, Group 2 (n = 13) with LMWH and Group 3, received no anti-coagulant drugs. The median duration of xenograft function was 20 days (range 3-62 days), 18 days (range 5-109 days) and 15 days (range 4-53 days) in Groups 1 to 3 respectively. Anti-coagulation achieved the targeted international normalized prothrombin ratio (INR) and anti-factor Xa levels consistent with effective in vivo therapy yet, no significant impact on median xenograft function was observed. At rejection, a similar histology of thrombosis and ischemia was apparent in each group and the levels of fibrin deposition and platelet thrombi in rejected tissue was the same. Anti-coagulation with warfarin or LMWH did not have a significant impact on the onset of DXR and microvascular thrombosis. However, a role for specific anti-coagulant strategies to achieve long-term xenograft function cannot be excluded. 相似文献
65.
66.
67.
68.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
69.
70.